768
Participants
Start Date
February 7, 2021
Primary Completion Date
September 30, 2025
Study Completion Date
April 30, 2026
Aspirin
Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
Placebo of aspirin
Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
WHO TBM treatment
2 months of (R-H-Z-E) + 7 months of (R-H)
Intensified TBM treatment
2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
NOT_YET_RECRUITING
Cocody University Hospital, Abidjan
RECRUITING
Treichville University Hospital, Abidjan
NOT_YET_RECRUITING
Yopougon University Hospital, Abidjan
RECRUITING
University Hospital Joseph Raseta Befelatanana, Antananarivo
RECRUITING
University Hospital Tambohobe, Fianarantsoa
NOT_YET_RECRUITING
Morafeno University Hospital, Toamasina
RECRUITING
Kayelitsha District Hospital, Cape Town
RECRUITING
Mitchells Plain Hospital, Cape Town
RECRUITING
New Somerset Hospital, Cape Town
RECRUITING
Dora Nginza Hospital, Port Elizabeth
RECRUITING
Livingstone and PE Central Hospitals, Port Elizabeth
RECRUITING
Mbarara Regional Reference Hospital, Mbarara
RECRUITING
Regional Reference Hospital of Kabale, Mbarara
European Union
OTHER
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
ANRS, Emerging Infectious Diseases
OTHER_GOV